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Abstract
Objective: An aging population and increasing use of percutaneous therapies have resulted in older patients with more co-
morbidity being referred for cardiac surgery. Objective measurements of physiological reserve and severity of co-morbid
disease are required to improve risk stratification. We hypothesised that FEV1 would predict mortality and length of stay
following cardiac surgery.
Methods: We assessed clinical outcomes in 2,241 consecutive patients undergoing coronary artery bypass grafting and/or
valve surgery from 2001 to 2007 in a regional cardiac centre. Generalized linear models of the association between FEV1 and
length of hospital stay and mortality were adjusted for age, sex, height, body mass index, socioeconomic status, smoking,
cardiovascular risk factors, long-term use of bronchodilators or steroids for lung disease, and type and urgency of surgery.
FEV1 was compared to an established risk prediction model, the EuroSCORE.
Results: Spirometry was performed in 2,082 patients (93%) whose mean (SD) age was 67 (10) years. Median hospital stay
was 3 days longer in patients in the lowest compared to the highest quintile for FEV1, 1.35-fold higher (95% CI 1.20–1.52;
p,0.001). The adjusted odds ratio for mortality was increased 2.11-fold (95% CI 1.45–3.08; p,0.001) per standard deviation
decrement in FEV1 (800 ml). FEV1 improved discrimination of the EuroSCORE for mortality. Similar associations were found
after excluding people with known pulmonary disease and/or airflow limitation on spirometry.
Conclusions: Reduced FEV1 strongly predicted increased length of stay and in-hospital mortality following cardiac surgery.
FEV1 is a widely available measure of physiological health that may improve risk stratification of complex patients
undergoing cardiac surgery and should be evaluated for inclusion in new prediction tools.
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Introduction
For more than 40 years cardiac surgery has been performed to
relieve symptoms and improve outcomes in patients with coronary
artery and valvular heart disease. [1] Whilst improvements in
surgical technique have resulted in progressive reductions in
operative morbidity and mortality, the aging population and
increasing use of percutaneous treatments have resulted in older
patients with more co-morbidity being referred for cardiac
surgery. [2].
Several prognostic indices have been developed to help patients
and clinicians decide whether cardiac surgery is appropriate. The
European System for Cardiac Operative Risk Evaluation (Euro-
SCORE) is a widely used risk prediction tool that comprises
seventeen clinical features, [3] and has good discrimination for
early and late post-operative mortality. [4] It is recognised that
changes in surgical practice over the last decade require these
clinical tools to be updated. [5] With increasingly elderly patients
being considered for surgical management, markers which reflect
general physiological reserve and severity of co-morbid disease
may be particularly relevant to prognosis and should be evaluated
for inclusion in new risk prediction tools.
Forced Expiratory Volume in one second (FEV1) is a robust
accurate measure of pulmonary physiology, and is a strong
predictor of mortality from cardiovascular, respiratory and other
causes, independent of age, gender, race/ethnicity, socioeconomic
status, blood pressure, diabetes and cholesterol, and has been
found to predict mortality in patients undergoing oesophagecto-
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my.[6–8] However, studies directly examining whether FEV1
predicts outcomes in cardiac surgery have been limited to small
numbers of patients with known pulmonary disease. [9,10] As
such, the relationship between FEV1 and clinical outcomes
following cardiac surgery has not been established, particularly
in patients without known pulmonary disease.
We hypothesised that FEV1 would predict length of hospital
stay and in-hospital mortality independent of a clinical history of
pulmonary disease and other potential confounders, and that the
addition of FEV1 to the EuroSCORE would improve risk
stratification in patients undergoing cardiac surgery.
Patients and Methods
Database Linkage was approved by Lothian Caldicott Officer
and the Chair of Lothian Research Ethics Committee advised that
the use of the fully irreversibly anonymised data for this research
did not require ethical approval by the full committee.
Study Population
In a retrospective cohort study we identified all patients aged 40
years or older who underwent coronary artery bypass grafting
(CABG) and/or valve repair or replacement surgery from January
1st 2001 to December 31st 2007 at the Royal Infirmary of
Edinburgh, Scotland, United Kingdom. Patients who were not
resident in the hospital catchment area or who underwent cardiac
surgery as an emergency were excluded a priori on the basis that
spirometry would not have been performed locally or would not
have been feasible prior to surgery. Where patients had more than
one operation during the study period, only the first operation was
included.
Clinical Characteristics and Outcomes
Patient characteristics and details of their cardiac surgery,
including length of hospital stay and in-hospital mortality, were
obtained from medical records and recorded in an electronic
cardiac surgical database (TOMCAT Clinical Systems, Philips
Healthcare, Amsterdam, The Netherlands) by trained staff at the
time of admission. Hospital stay was defined as a single continuous
NHS stay following surgery, excluding long-term facilities. In-
hospital mortality was defined as any death within this stay. This
database is maintained to nationally agreed standards, which
includes auditing of randomly sampled medical records and
publication of statistics on missing data (www.scts.org/sections/
audit/Cardiac/index.html). In an external Scottish Quality
Improvement Programme audit in 2008 these data were found
to be 98.5% accurate.
An estimate of predicted operative mortality was derived using
the EuroSCORE (excluding the following variables which were
not included in the linked dataset - active endocarditis, critical pre-
operative state, or post-infarct septal rupture). [5](3) The Euro-
SCORE defines ‘chronic pulmonary disease’ as the long term use
of bronchodilators or steroids for lung disease. Patient or clinician
reported diagnoses of chronic obstructive pulmonary disease
(COPD) and asthma were also recorded. The 2006 Scottish Index
of Multiple Deprivation (SIMD) score was obtained from the
recorded postal code and patients were stratified based on the
national distribution of the SIMD in order to provide an area-
based measure of socio-economic status (www.scotland.gov.uk/
Publications/2005/10/1893201/32023).
Spirometry
Height and weight were measured, and spirometry was
performed on a wedge bellows spirometer to Association for
Respiratory Technology and Physiology/British Thoracic Society
standards (Model S, Vitalograph, Buckinghamshire UK) by
trained clinical physiologists in one of two pulmonary function
laboratories. FEV1 percent predicted was calculated using the
European Coal and Steel reference equations. [11] Airflow
obstruction was defined a priori as an FEV1/FVC ratio below
0.7 and FEV1 percent predicted less than 80% according to UK
national guidance (http://guidance.nice.org.uk/CG12). A broad-
er definition of airflow obstruction for use in sensitivity analyses
included all patients with an FEV1/FVC ratio below 0.7 regardless
of the FEV1 percent predicted. We did not measure post
bronchodilator spirometry, and therefore in order to estimate
the likely prevalence of COPD according to international
guidelines (www.goldcopd.com and www.thoracic.org/clinical/
copd-guidelines), which require post-bronchodilator spirometry,
we used the difference in prevalence of airflow obstruction
between pre and post bronchodilator spirometry in the interna-
tional PLATINO COPD prevalence study [12] to adjust the
proportion of patients with FEV1/FVC ratio below 0.7 in our
cohort.
Record Linkage
Records from the cardiac surgery database were linked to the
spirometry database for the same period. Within a secure health
service environment, date of birth, first name and surname were
used to link records using Microsoft Access 2000. Personal
identifiers and dates were removed following linkage and the
irreversibly anonymised database was used for analysis. Where
patients had spirometry performed more than once prior to
surgery, the measure closest to the date of the operation was
selected. Patient selection and matching were completed prior to
all analyses.
Statistical Analysis
For descriptive purposes, characteristics were compared for
patients with and without spirometry records and by quintile of
FEV1 percent predicted, which is widely used in clinical practice.
However, use of the current European prediction equations has
been criticised on the grounds that they are not contemporary and
were not obtained from original data. [13] As such, all formal
analyses were performed using FEV1 with adjustment for age, sex,
height and other covariates as appropriate. Proportional change in
length of stay, and the odds ratio for in-hospital mortality were
estimated by quintile of FEV1, and per one standard deviation
decrement in FEV1, using linear regression of length of stay (log-
transformed) and logistic regression respectively.
Although most epidemiological studies report FEV1 as the
primary marker of impaired lung function, controversy continues
as to whether FEV1, FVC or the FEV1/FVC ratio is the best
predictor of mortality in populations not selected to have chronic
lung disease. [14,15] As such, the analyses were repeated with
FVC and the FEV1/FVC ratio in addition to and as an alternative
to the FEV1.
Discrimination of the existing EuroSCORE model was com-
pared to a model including EuroSCORE and FEV1 using the area
under the curve, [16] and the more sensitive net reclassification
and integrated discrimination indices (NRI and IDI respectively).
[17] The NRI compares models with and without a new marker of
interest to estimate the proportion of patients more appropriately
classified minus the proportion less appropriately classified under
the new model. The IDI is a global measure of sensitivity weighted
by specificity that is more sensitive than the area under the curve.
Model calibration was compared using the le Cessie-van
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Houwelingen normal test statistic for the unweighted sum of
squared errors [18].
In sensitivity analyses regression modelling was repeated
following stratification by gender, smoking status, type and
urgency of operation, and following exclusion of patients with a
clinical history of asthma, COPD and long-term use of broncho-
dilators or steroids for lung disease, or airflow obstruction on
spirometry. Generalised additive models were used to explore non-
linearity. Where data were missing, multiple imputation was used
as the main approach with listwise deletion sensitivity analyses.
Analyses were performed in SAS 9.2 (Cary, North Carolina, USA)
and R version 2.9.2 (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Records meeting matching criteria were available for 2,082
patients (93%) of the 2,241 patients from the regional cardiac
surgery database who met the eligibility criteria. The 159 patients
without spirometry were more likely to have required urgent
surgery (70 versus 54%, p,0.001), and have a clinical history of
COPD (3.8 versus 1.3%, p = 0.02), but were otherwise similar to
the 2,082 with matching records.
In patients with spirometry performed the mean (SD) age was
67 (10) years and 1,451 (70%) were male (Table 1). Spirometry
was performed in the same year as surgery in 90% of patients, and
in the same or previous year in 97% (median (IQR) 3 (1 to 5)
months after angiography). Most patients had a history of cigarette
smoking with 52% ex-smokers and 15% current smokers, but a
clinical diagnosis of COPD was only recorded in 28 (1.3%),
asthma in 24 (1.2%) and long-term use of bronchodilators or
steroids for lung disease in 20 (1.0%) patients. Airflow obstruction
identified on spirometry (FEV1/FVC ,0.7 and FEV1,80%
predicted) was present in 318 (15%) patients, of these 80% had an
FEV1.50% predicted, 17% had an FEV1 30–49% predicted and
3% had an FEV1 of ,30%.
Using the broader definition of airflow obstruction requiring an
FEV1/FVC ratio below 0.7 regardless of the FEV1 percent
predicted, 511 (25%) patients had airflow limitation. Adjusting this
estimate to account for the fact that a bronchodilator was not
administered prior to spirometry [12] an estimated 18% of
patients had airflow obstruction according to current international
guidelines [19,20] (Table S1).
Socioeconomic deprivation, urgent surgery, valve procedures,
current smoking, diabetes mellitus, stroke, extra-cardiac arteriop-
athy (a history of claudication, documented carotid artery
occlusion or .50% stenosis, or surgery for disease of the
abdominal aorta, peripheral vasculature or carotid arteries), left
ventricular impairment, pulmonary hypertension (systolic blood
pressure .60 mmHg), atrial fibrillation and dyspnoea were more
frequent in quintiles with lower FEV1 percent predicted than those
in higher quintiles, but the proportion of patients with a .70%
stenosis in one or more of the main coronary arteries was similar
across FEV1 percent predicted quintiles (Table 1).
Length of Stay
Median hospital stay was 3 days longer amongst patients in the
lowest quintile for FEV1 compared to patients in the highest
quintile (1.53-fold longer; 95% CI 1.41–1.67; p,0.001), and this
association persisted after adjusting for age, sex, height, body mass
index, type of operation, urgency of procedure, deprivation score,
smoking status, recent myocardial infarction, extracardiac arteri-
opathy, diabetes, hypertension, stroke, atrial fibrillation, left
ventricular function, asthma, COPD, bronchodilator use, preop-
erative renal failure, and pre-operative angina and dyspnoea (1.35-
fold longer; 95% CI 1.20–1.52; p,0.001) (Table 2).
Mortality
Strong associations were found for in-hospital mortality and
FEV1 (Table 3). The unadjusted odds ratio (OR) for in-hospital
death was 2.58-fold higher (95% CI 1.95–3.41; p,0.001) per
standard deviation decrement in FEV1 (800 ml). FEV1 remained a
strong predictor after adjusting for type of operation, smoking
status, asthma, COPD, bronchodilator use, pre-operative angina
and pre-operative dyspnoea (OR 2.11; 95%CI 1.45–3.08;
p,0.001).
Airflow Obstruction on Spirometry and FEV1
Adjusting for the same covariates as in the main analyses, FEV1
continued to predict hospital stay (800 ml decrement in FEV1;
1.26-fold longer; 95% CI 1.08–1.48, p,0.001), and mortality
(800 ml decrement in FEV1; 2.28 OR; 95% CI; 1.19–4.41;
p = 0.01) after excluding individuals with airflow obstruction on
spirometry. Similar results were obtained when a broader
definition of airflow obstruction was used (FEV1/FVC ratio
,0.70, regardless of FEV1 percent predicted, p,0.001, and
p = 0.01 respectively).
Moreover, there was no suggestion that increased risk was
confined to patients with low lung function (Figure 1). There was a
suggestion of an inflection for both mortality and length of stay at
higher levels of FEV1 (4 litres and above) but the data were
relatively sparse at this level, the odds ratio for mortality continued
to decline, and there was not statistically significant evidence of
departure from linearity for either hospital stay or mortality
(p = 0.13, and p = 0.28 respectively). Similar results were obtained
following exclusion of patients with a clinical history of asthma,
COPD, long-term use of bronchodilators or steroids for lung
disease, or airflow obstruction (defined as FEV1/FVC ,0.7) on
spirometry (Figure 2).
In addition, similar associations were found among never
smokers as among smokers and ex-smokers for length of stay (1.09-
fold longer; 95% CI 1.01 to 1.07 and 1.13-fold longer; 95% CI
1.07 to 1.19 respectively) and mortality (OR 2.29; 95% CI 1.00 to
2.58 and OR 2.45; 95% CI 1.55 to 3.95 respectively), indicating
that smoking related airflow obstruction is unlikely to be the major
driver of the association between pulmonary function and
outcomes.
FVC and the FEV1/FVC Ratio
In the fully adjusted models we obtained similar associations for
hospital stay (1 SD decrement in FVC; 1.10-fold longer; 95% CI
1.06 to 1.16, p,0.001) and for mortality (1 SD decrement OR
2.04; 95% CI 1.35 to 3.08) for the FVC alone as we did for FEV1.
Similar, but weaker associations were found for hospital stay and
mortality for FEV1/FVC alone compared to FEV1 (p = 0.006,
p = 0.06 respectively).
However, neither the FVC nor the FEV1/FVC ratio added
significantly to the FEV1 for hospital stay (p = 0.97 and p = 0.84
respectively) or mortality (p = 0.12 and p = 0.57 respectively).
FEV1 Compared to the EuroSCORE
FEV1 remained strongly associated with mortality after
adjusting for the EuroSCORE (OR 1.69; 95% CI 1.23–2.31,
likelihood ratio statistic 11, 1 df, p,0.001). The area under the
receiver operator characteristic curve (AUC) was higher for
EuroSCORE than FEV1, but the difference was not statistically
significant (AUC 0.78 and 0.74 respectively, p = 0.15). Similarly,
FEV1 Predicts Mortality following Cardiac Surgery
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the addition of FEV1 to the EuroSCORE increased the AUC
when compared to the EuroSCORE alone (AUC of 0.80 and 0.78
respectively), but the difference was not statistically significant
(p = 0.26).
However, comparing the area under the curve is known to be
insensitive, hence some authors recommend the inclusion of more
sensitive measures of discrimination (23) such as the Net
Reclassification Index (NRI), [17] according to which 27% of
patients (95% CI 4–51%, p,0.001) were more appropriately
Table 1. Patient characteristics by quintile of FEV1 percent predicted.
Q1 Q2 Q3 Q4 Q5
FEV1% predicted, mean (range) 60 (20–75) 82 (75–88) 93 (88–98) 102 (98–108) 120 (109–177)
n 416 417 416 417 416
Age, years (mean (SD)) 69 (9) 66 (10) 66 (10) 66 (10) 68 (10)
Gender, male 68.3 70.0 71.4 72.4 66.4
Deprivation (SIMD)
First quintile (most deprived) 18 12 9 14 8
Second quintile 24 21 24 22 17
Third quintile 14 17 18 12 15
Fourth quintile 18 23 20 18 22
Fifth quintile (least deprived) 27 28 30 25 39
Height, cm – mean (SD) 168 (9) 168 (9) 168 (9) 168 (9) 166 (10)
Body mass index, kg/m2 (mean (SD)) 27.1 (4.9) 28.7 (4.7) 28.1 (4.4) 28.0 (4.6) 27.6 (4.3)
Smoking status
Never smoked 23 28 34 37 45
Ex-smoker 59 53 50 50 48
Current smoker 19 19 16 13 7
Previous cardiac surgery 8.4 7.9 5.5 2.6 2.4
Diabetes 19 18 17 16 13
Hypertension 59 66 64 63 67
Renal disease 5 1 1 1 1
Previous stroke or TIA 15 9 11 11 6
Extracardiac arteriopathy 11 12 10 8 6
Recent myocardial infarction 63 60 58 60 57
Atrial fibrillation 27 17 13 14 6
Recorded COPD diagnosis 2.6 1.4 1.4 0.5 0.7
Recorded asthma diagnosis 2.2 1.4 1.0 0.2 1.0
Long-term use of bronchodilators or steroids for lung
disease
2.4 1.0 0.2 0.7 0.5
Vessels .70% stenosis
None 31 23 22 23 21
One 8 9 7 6 10
Two 16 17 16 19 18
Three 44 51 54 52 51
Left ventricular ejection fraction
Normal 61 69 72 72 78
Moderately impaired 28 22 24 25 17
Severely impaired 11 9 5 3 5
Pulmonary hypertension (systolic BP.60 mmHg) 30 27 20 6 11
Type of operation
CABG 53.6 63.1 67.6 67.9 67.3
CABG and valve 14.2 13.0 12.3 10.3 13.2
Valve 32.2 24.0 20.2 21.8 19.5
Urgent surgery 59.6 52.0 55.3 52.3 50.5
Values are percentage unless stated.
doi:10.1371/journal.pone.0064565.t001
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classified with the EuroSCORE alone than with FEV1 alone,
while 36% of patients (95% CI 12–59%; p = 0.003) were more
appropriately classified when FEV1 was combined with the
EuroSCORE compared to the EuroSCORE alone. The Integrat-
ed Discrimination Index yielded similar results for each of these
comparisons: EuroSCORE alone versus FEV1 alone (IDI 0.02;
95% CI 0.00–0.03; p = 0.01) and EuroSCORE alone versus FEV1
in combination with EuroSCORE (IDI = 0.01; 95% CI 0.00–0.02;
p = 0.006). Model calibration was also better with FEV1 and
EuroSCORE combined (z = 0.14; p = 0.89) than with the Euro-
SCORE alone (z = 1.27, p = 0.21).
Sensitivity Analyses
After stratifying by operation type similar associations were
found for length of stay (800 ml decrement in FEV1; 1.10-fold
longer [95% CI 1.01 to 1.21] and 1.12-fold longer [95% CI 1.07
to 1.17] for patients with and without valve surgery respectively)
and mortality (1 SD decrement; OR 2.58 [95% CI 1.59 to 4.29]
and OR 1.88 [95% CI 0.95 to 3.69] for patients with and without
valve surgery respectively). Nor did stratification for urgency of
procedure or gender reveal evidence of effect measure heteroge-
neity. Repeating analyses without adjustment for height yielded
very similar associations for FEV1 for hospital; stay and mortality.
Results obtained using listwise deletion were similar to those
obtained using multiple imputation.
Discussion
FEV1 is a strong predictor of longer hospital stay and in-hospital
mortality following elective and urgent cardiac surgery. These
associations persist after adjusting for multiple covariates including
a clinical diagnosis of COPD, and airflow obstruction on
spirometry. Addition of FEV1 to the current and most widely
used peri-operative risk prediction model, the EuroSCORE,
improved discrimination and calibration for in-hospital mortality.
COPD is the commonest cause of reduced FEV1, [21] and is an
established risk factor for in-hospital and long-term mortality
following cardiac surgery.[22–24] Two recent studies reported
that FEV1 was associated with poorer outcome in patients with
chronic lung disease undergoing cardiac surgery, but due to the
Table 2. Length of stay (LOS) by quintile of FEV1.
Q1 Q2 Q3 Q4 Q5
SD decrement in
FEV1 P-value
FEV1 litres, mean (range) 1.31 (0.35–1.70) 1.95 (1.71–2.20) 2.41 (2.21–2.62) 2.89 (2.63–3.15) 3.57 (3.16–5.80) (800 ml)
n 416 417 416 417 416
LOS in days, median (IQR) 10 (7–15) 8 (7–13) 7 (6–10) 7 (6–9) 7 (6–8)
Relative LOS unadjusted 1.53 1.40 1.25 1.10 1 1.17 ,0.001
(95% CI) (1.41–1.67) (1.29–1.52) (1.15–1.36) (1.01–1.20) 1.14–1.20
Relative LOS - model 1 1.53 1.38 1.21 1.07 1 1.17 ,0.001
(95% CI) (1.36–1.71) (1.25–1.53) (1.11–1.33) (0.98–1.16) 1.12–1.21
Relative LOS - model 2 1.35 1.30 1.16 1.05 1 1.12 ,0.001
(95% CI) (1.20–1.52) (1.17–1.44) (1.05–1.27) (0.96–1.14) 1.07–1.17
Relative LOS – proportional change in length of stay relative to reference category.
Model 1 - adjusted for age, sex, height and body mass index.
Model 2– as model 2 additionally adjusting for type of operation, urgency of procedure, deprivation score, smoking status, recent myocardial infarction, extracardiac
arteriopathy, diabetes, hypertension, stroke, atrial fibrillation, left ventricular function, asthma, COPD, long-term use of bronchodilators or steroids for lung disease,
preoperative renal failure, pre-operative angina, pre-operative dyspnoea.
doi:10.1371/journal.pone.0064565.t002
Table 3. In-hospital mortality by quintile of FEV1.
Q1 Q2 Q3 Q4 Q5
SD decrement
in FEV1 P-value
FEV1 litres, mean (range) 1.31 (0.35–1.70) 1.95 (1.71–2.20) 2.41 (2.21–2.62) 2.89 (2.63–3.15) 3.57 (3.16–5.80) (800 ml)
n 416 417 416 417 416
Mortality, n (%) 36 (8.7%) 16 (3.8%) 12 (2.9%) 3 (0.7%) 4 (1.0%)
Odds Ratio unadjusted 9.76 4.11 3.06 0.75 1 2.58 ,0.001
(95% CI) (3.44–27.7) (1.36 12.41) (0.98–9.57) (0.17–3.36) 1.95–3.41
Odds Ratio - model 1 8.61 3.73 2.94 0.74 1 2.53 ,0.001
(95% CI) (2.58–28.81) (1.13–12.33) (0.91–9.53) (0.16–3.36) 1.78–3.60
Odds Ratio - model 2 5.23 2.76 2.28 0.69 1 2.11 ,0.001
(95% CI) (1.48–18.41) (0.81–9.36) (0.69–7.53) (0.15–3.15) 1.45–3.08
Model 1 - adjusted for age, sex, height and body mass index.
Model 2 - as model 1 additionally adjusting for type of operation, smoking status, COPD, long-term use of bronchodilators or steroids for lung disease, pre-operative
angina, pre-operative dyspnoea.
doi:10.1371/journal.pone.0064565.t003
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small number of patients with measured FEV1 (n,150), linearity
was not assessed and adjustment for potential confounders was
limited. [9,10] Abadag et al [25] found that pulmonary function
predicted increased mortality and length of stay in patients with
cardiac surgery, but less than 45% of patients had spirometry
measured, with the decision to measure pulmonary function
having been made at each clinician’s discretion, making selection
bias likely. Moreover, no comparisons within individuals with
normal lung function were made. We examined the association
between FEV1 and both hospital stay and in-hospital mortality
across the spectrum of lung function, and found no evidence for a
plateau at least until FEV1 was moderately high (3–4 litres), and
that FEV1 predicted hospital stay and mortality even after
excluding patients with any evidence of airflow obstruction on
spirometry. This association persisted after controlling for other
potentially important confounders including age, sex, cardiovas-
cular risk factors and socioeconomic status.
In order to explore the potential usefulness of FEV1 for
inclusion in risk prediction tools, we also examined the effect of the
addition of FEV1 on discrimination (distinguishing patients with
and without adverse events) and calibration (precision of estimates
of risk of adverse events). [26] In a recent review of nineteen
published risk prediction models the EuroSCORE was found to be
the best discriminator for 30-day and one year mortality after
cardiac surgery. [4] We found that FEV1 when combined with
EuroSCORE improved discrimination compared to EuroSCORE
alone. The area under the curve was higher, although the
difference was not statistically significant, while the more powerful
Net Reclassification Index was highly statistically significant, and
estimated that over a third of patients would be assigned a more
appropriate risk of in hospital death when FEV1 was combined
with the EuroSCORE compared to the EuroSCORE alone.
Calibration was also improved on adding FEV1 to the Euro-
SCORE. FEV1 appears to have additional value, beyond
identifying patients with chronic lung disease, as an independent
predictor of outcome in patients undergoing cardiac surgery.-
Moreover, FEV1 is not a costly new biomarker, but rather a widely
available physiological measurement which we found was
routinely performed in over 90% of patients undergoing elective
and urgent cardiac surgery. FEV1 remains stable over time and
can therefore be measured at an early stage of evaluation prior to
cardiac surgery [27] and is therefore an attractive candidate for
inclusion in prognostic models.
Figure 1. Relationship between FEV1, length of stay and mortality. a) Relative length of stay for a given FEV1 compared to the length of stay
for the mean FEV1. b) Odds ratio for in-hospital mortality for a given FEV1 compared to the odds ratio for the mean FEV1. Estimates were obtained
from generalized additive models using a loess smoothing function. A rug plot illustrates the density of the data for given value of FEV1. Significance
tests for non-linearity were p = 0.13 and p= 0.28 respectively.
doi:10.1371/journal.pone.0064565.g001
Figure 2. Barplots of association between FEV1, and mortality
in patients with and without a diagnosis of COPD or asthma,
long-term use of bronchodilators or steroids for lung disease,
and airflow obstruction on spirometry. Estimates were obtained
from generalized linear models adjusting for age, sex, height and body
mass index, type of operation, smoking status, pre-operative angina,
pre-operative dyspnoea, and, except where these patients were
excluded, COPD and long-term use of bronchodilators or steroids for
lung disease.
doi:10.1371/journal.pone.0064565.g002
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COPD particularly when mild or moderately severe is
commonly under-diagnosed in primary care, [18] and the same
appears to be true for patients undergoing cardiac surgery. Fewer
than 2% had known COPD, lower than the 5% we would have
expected based upon the age-sex distribution of our patients and
national statistics on the proportion of patients diagnosed with
COPD in this region of Scotland (www.isdscotland.org/isd/3707.
html). Patients with clinically evident COPD may be less
frequently selected for cardiac surgery. Nevertheless, fifteen
percent had airflow obstruction on spirometry and a significant
proportion of these are likely to have had COPD. As such, under-
treatment of mild to moderate COPD (with, for example
inadequate inhaled therapy) may contribute to the excess mortality
associated with low FEV1, and the routine recording of spirometry
during pre-assessment for surgery may improve treatment and
clinical outcomes in these patients.
Undiagnosed COPD is unlikely to be the primary cause of
excess morbidity and mortality since FEV1 predicted outcomes
similarly well in patients without airflow obstruction, and among
never smokers. Furthermore, similar associations were found for
FVC as for FEV1, and the FEV1/FVC ratio did not have
additional power over FEV1 alone. Reductions in FEV1 (and
FVC) may reflect both increased exposure and susceptibility to
pro-inflammatory factors, such as cigarette smoking, environmen-
tal pollution and microbial infection. FEV1 may also be influenced
by pulmonary congestion secondary to valvular heart disease
related which can cause both obstructive and restrictive abnor-
malities in pulmonary function. [28].
Alternatively, as previously suggested, reduced FEV1 may
simply be an indicator of the patients’ capacity to withstand the
insult of major surgery, reflecting their respiratory reserve,
nutritional status or muscle strength. [14,15] In the general
population FEV1 predicts a range of adverse outcomes including,
but not limited to cardiovascular, respiratory and even psychiatric
illness. [6] Moreover, pulmonary function as measured by
spirometry depends not only on lung characteristics such as
airway diameter and lung elasticity, but also on skeletal muscle
strength [29] (in the diaphragm and intercostal muscles) while
pulmonary function also improves following bariatric surgery. [30]
Therefore, we believe that FEV1 (and FVC) is likely to reflect the
patient’s general capacity to withstand the insult of major surgery,
and not just respiratory reserve.
FEV1 and FVC were highly correlated, and performed
similarly in predicting length of hospital stay and mortality.
However, the FEV1/FVC ratio was less strongly associated with
these outcomes. As such, while FEV1/FVC is required, by
definition to diagnose COPD, it appears be less useful than
FEV1 and FVC as a prognostic marker following cardiac
surgery, particularly if a single cut-off value (such as FEV1/
FVC ,0.7) is used. Therefore, cardiac surgery departments
should consider recording the FEV1 and FVC in addition to
the FEV1/FVC ratio. Although further multi-centre studies will
be required to confirm that future cardiac surgery scores should
include pulmonary function measures. Future studies examining
cause-specific mortality and complication rates will also allow us
to explore the mechanisms underlying the associations with
FEV1 and mortality and length of stay.
Limitations
Not all patients had FEV1 measured immediately prior to
surgery. However, most patients had FEV1 measured as part of
their surgical pre-assessment, and the decline of FEV1 in both the
general population and patients with COPD is low (approximately
30 ml/year [27,31]) Changes in FEV1 between pre-assessment
spirometry and the date of surgery, for example because patients
are started on bronchodilator therapy, are likely to underestimate
the strength of association with mortality and length of stay.
We did not record all known prognostic markers at the time
of the matching and anonymisation, and did not include active
endocarditis, critical pre-operative state, or post-infarct septal
rupture in our EuroSCORE calculation. However, these clinical
variables are present in less that 0.1% of patients undergoing
urgent cardiac surgery in our regional centre (results not shown)
and similar associations for FEV1 and length of stay and
mortality were found even when restricting the analysis to
elective surgery, making confounding by these ‘critical illness’
variables unlikely.
The purpose of this study was not to estimate the prevalence of
under-diagnosis of COPD. However, we report the prevalence of
airflow obstruction using UK COPD guidance current to the year
of surgery for our patients (FEV1/FVC ,0.7 and FEV1 less than
80% predicted). [32] Updated UK guidance and international
guidelines [19,20] do not require an FEV1 less than 80%
predicted, but do stipulate the use of post bronchodilator
spirometry. Nevertheless, we were able to adjust for the use of
non-post bronchodilator spirometry using data from the interna-
tional PLATINO study [12] to estimate that approximately 18%
of patients are likely to have had post-bronchodilator obstruction,
and therefore meet the current international criteria for diagnosis
of COPD. However, importantly FEV1 predicted mortality and
morbidity as well in patients without airflow obstruction (FEV1/
FVC,0.7 and any report of asthma or COPD), and in never
smokers as in the full cohort (Figure 2), suggesting that FEV1 is
more likely to be a marker of frailty than solely a marker of airflow
obstruction.
Conclusions
FEV1 is a strong and independent predictor of length of stay
and in-hospital mortality following elective and urgent cardiac
surgery, and improves the discrimination of existing risk prediction
tools. Spirometry is a widely available non-invasive measure of
physiological reserve that is commonly performed in older patients
undergoing major surgery. FEV1 should be formally evaluated for
inclusion in new cardiac surgery risk prediction tools with the goal
of improving clinical outcomes in complex patients undergoing
cardiac surgery.
Supporting Information
Table S1 Comparison of prevalence of airflow obstruc-
tion (FEV1/FVC ,0.7, ie COPD) in cardiac surgery
patients compared to the prevalence of airflow obstruc-
tion with and without administration of a bronchodila-
tor in an international prevalence study. BD – broncho-
dilator PLATINO – burden of obstructive lung disease.
PLATINO defined low-risk subjects (a total of 1895) as patients
who were asymptomatic, with low cigarette smoke exposure (,10
pack years, ,200 hour-years of biomass smoke, ,5 years exposed
to dust) and who had no reported asthma or COPD. The
remaining subjects were considered high-risk. We defined low risk
as never smokers, and high risk as all other patients. * For each
stratum the prevalence of airflow obstruction among the cardiac
surgery patients was multiplied by the ratio of pre to post
bronchodilator defined airflow obstruction from the PLATINO
study to obtain the estimated prevalence of airflow obstruction on
post-bronchodilator spirometry.
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